FDA Approves XPOVIO — Karyopharm Therapeutics Inc.

# FDA Approves Karyopharm Therapeutics' XPOVIO (selinexor) for Multiple Myeloma Karyopharm Therapeutics Inc. received FDA approval for XPOVIO (selinexor), an oral selective inhibitor of nuclear export, marking the company's first commercial product and opening a potential new market segment in multiple myeloma treatment. The approval positions Karyopharm to compete in the hematologic malignancy space and could validate its XPO1 inhibition platform for additional oncology indications.